Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3

Nature Medicine

Volumn 7, Issue 2, 2001, Pages 199-205

  Mäkinen, Taija ^a   Jussila, Lotta ^a   Veikkola, Tanja ^a   Karpanen, Terhi ^a   Kettunen, Mikko I ^b   Pulkkanen, Kalevi J ^b,c   Kauppinen, Risto ^b   Jackson, David G ^d   Kubo, Hajime ^e   Nishikawa, Shin Ichi ^e   Ylä Herttuala, Seppo ^b   Alitalo, Kari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; SOLUBLE VASCULOTROPIN RECEPTOR 3; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL REGENERATION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; LYMPH FLOW; LYMPHEDEMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; ENDOTHELIAL GROWTH FACTORS; HUMANS; LYMPH NODES; LYMPHEDEMA; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

ANIMALIA; MUS MUSCULUS;

EID: 0035122695     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/84651     Document Type: Article

References (47)

1. Molecular and biological properties of vascular endothelial growth factor
2. Mechanisms of angiogenesis and arteriogenesis
3. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors
4. Regulation of angiogenesis via vascular endothelial growth factor receptors
5. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice
6. Failure of blood island formation and vasculogenesis in Flk-1-deficient mice
7. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3
8. Expression of the fms-like tyrosine kinase FLT4 gene becomes restricted to lymphatic endothelium during development
9. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues
10. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
11. VEGF and VEGF-C: Specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane
12. Missense mutations interfere with VEGFR-3 signaling in primary lymphoedema
13. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase
14. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
15. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
16. Vascular endothelial growth factor is essential for corpus luteum angiogenesis
17. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor
18. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor
19. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
20. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ
21. Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3
22. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3
23. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis
24. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan
25. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
26. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: Implications for the in vivo detection of apoptosis
27. Programming gene expression in developing epidermis
28. Endothelial-specific gene expression directed by the tie gene promoter in vivo
29. VEGF is required for growth and survival in neonatal mice
30. Lymphangiogenesis: Mechanisms, significance and clinical implications
31. The pathophysiology of lymphedema
32. Molecular regulation of lymphangiogenesis and targets for tissue oedema
33. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF
34. Proteolytic processing regulates receptor specificity and activity of VEGF-C
35. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
36. Vascular endothelial growth factor C induces angiogenesis in vivo
37. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia
38. C-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro
39. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities
40. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors
41. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer
42. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
43. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer
44. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis
45. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis
46. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
47. VEGF-D promotes the metastatic spread of cancer by lymphatics